Amendments to the Claims

1. (Currently amended) An anti-coagulant comprising a sulfated polysaccharide ~~obtained by using a raw material of a polysaccharide having a structural unit in which an abundance ratio of glucose, glucuronic acid and rhamnose is 2 : 1 : 1 mole to sulfate 8 to 80 % of a hydroxyl group contained in the above raw material polysaccharide~~ or a compound having the sulfated polysaccharide as a partial structure, where the sulfated polysaccharide is obtained by sulfating 8 to 80 % of hydroxyl groups of a raw material polysaccharide having a structural unit in which a mole ratio of glucose, glucuronic acid and rhamnose is 2 : 1 : 1, and the raw material polysaccharide is hydrolyzed before sulfating the raw material polysaccharide.

2. (Original) The anti-coagulant as described in claim 1, wherein the raw material polysaccharide is a polysaccharide having a structural unit represented by the following Formula (1):



(1)

3. (Original) The anti-coagulant as described in claim 1, wherein the raw material polysaccharide is gellan.

4. (Currently amended) The anti-coagulant as described in claim 1, comprising the polysaccharide obtained by sulfating 20 to 50 % of ~~a~~ hydroxyl ~~group~~ groups contained in the raw material polysaccharide or the compound having the sulfated polysaccharide as a partial structure.

5. (Original) The anti-coagulant as described in claim 1, wherein the sulfated polysaccharide has a mean molecular weight of 1 to 1000 KDa.

6. (Original) The anti-coagulant as described in claim 1, wherein the sulfated polysaccharide has a mean molecular weight of 1 to 30 KDa.

7. (Currently amended) An anti-thrombus agent comprising the anti-coagulant as described in any of claims 1 to 6 and a carrier.

8. (Cancelled)

9. (Currently amended) ~~The anti-thrombus agent as described in claim 7 or 8, obtained by processing the anti-coagulant into the form of a~~ A unit preparation of the anti-thrombus agent as described in claim 7 for intravenous administration, intestinal administration or oral administration.

10. (Original) A blood contact face-treating agent for medical equipment, comprising the anti-coagulant as described in any of claims 1 to 6.

11. (Withdrawn) Medical equipment treated using the blood contact face-treating agent as described in claim 10.

12. (Withdrawn) A catheter, an injector for collecting blood, an artificial organ, an infusion pack or an infusion tube treated using the blood contact face-treating agent as described in claim 10.

13. (New) A method for treatment of myocardial infarction, cerebral infarction or venous thrombosis in a patient, which comprises administering an effective amount of the anti-thrombus agent of claim 7 to the patient.